Diagnosis & Disease Information

Fast Track for New Prostate Cancer Therapy

The FDA has assigned priority review status to the Biologics License Application for Provenge (sipuleucel-T), an investigational immunotherapy for asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer.

Pre-ESRD Care Cuts Early Mortality

Patients with end-stage renal disease (ESRD) are at higher risk of death within the first 120 days of hemodialysis compared with 121-365 days after hemodialysis initiation, according to a report.

Next post in News